By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


SEARCH JOBS

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.


Key Statistics


Email: Info@junotherapeutics.com
Ownership: Private

Web Site: Juno Therapeutics
Employees: n/a
Symbol: JUNO
 



Industry
Biotechnology






Company News
Four Seattle Biotech Firms Looking to Hire Hundreds of New Employees 5/21/2015 6:31:28 AM
Juno Therapeutics (JUNO) Reports First Quarter 2015 Financial Results 5/11/2015 4:34:08 PM
White-Hot Juno Therapeutics (JUNO) Goes Shopping Again, Shelling Out $81 Million for Stage Cell Therapeutics 5/11/2015 2:47:19 PM
Juno Therapeutics (JUNO) To Present At The Bank of America (BAC) Merrill Lynch 2015 Health Care Conference 5/6/2015 1:46:49 PM
$60 Million Juno Therapeutics (JUNO) Deal Pushes Fate Therapeutics (FATE) Up 80% in Premarket Trading 5/6/2015 7:31:10 AM
Juno Therapeutics (JUNO) To Report First Quarter 2015 Financial Results On Monday, May 11 5/5/2015 10:17:46 AM
MedImmune (AZN) And Juno Therapeutics (JUNO) Announce Immuno-Oncology Clinical Trial Collaboration 4/23/2015 6:32:17 AM
Juno Therapeutics (JUNO)' CAR T Cell Product Candidate JCAR017 Continues To Demonstrate Encouraging Outcomes In Pediatric Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia 4/21/2015 10:14:30 AM
CAR-T Cell Companies Juno Therapeutics (JUNO), Kite Pharma (KITE), and ZIOPHARM, Inc. Get Stock Jitters on Disappointing Novartis AG (NVS) Trial News 4/21/2015 6:39:03 AM
Roaring Juno Therapeutics (JUNO) Ends Quest for New Headquarters and Blueprints Plans to Keep Investors Happy 4/9/2015 5:10:53 AM
12345
//-->